Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study

Hypertension

Volumn 45, Issue 2, 2005, Pages 198-202

  Ibsen, Hans ^a   Olsen, Michael H ^a   Wachtell, Kristian ^a   Borch Johnsen, Knut ^b   Lindholm, Lars H ^c   Mogensen, Carl Erik ^d   Dahlöf, Björn ^e   Devereux, Richard B ^f   De Faire, Ulf ^g   Fyhrquist, Frej ^h   Julius, Stevo ⁱ   Kjeldsen, Sverre E ^j   Lederballe Pedersen, Ole ^k   Nieminen, Markku S ^h   Omvik, Per ^l   Oparil, Suzanne ^m   Wan, Ying ⁿ  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k VIBORG HOSPITAL   (Denmark)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Albuminuria; Angiotensin antagonist; Blood pressure; Cardiovascular diseases

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; CREATININE; LOSARTAN;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; MONITORING; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; STROKE;

EID: 19944432108     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000154082.72286.2a     Document Type: Article

References (19)

1. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens. 2002;20:353-355.
2. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35:898-903.
3. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901-906.
4. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
5. Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens. 2002;20:405-412.
6. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Lond). 1995;88:629-633.
7. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103:1869-1874.
8. Dahlöf B, Devereux RB, Kjeldsen SE, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
9. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, Gerdts E, Wright JT Jr, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J. 2002;143:319-326.
10. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? J Hypertens. 2004;22:1805-1811.
11. Bulatov VA, Stenehjem A, Os I. Left ventricular mass assessed by electrocardiography and albumin excretion rate as a continuum in untreated essential hypertension. J Hypertens. 2001;19:1473-1478.
12. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285-2293.
13. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617-624.
14. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
15. Yuyun MF, Dinneen SF, Edwards OM, Wood E, Wareham NJ. Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med. 2003;20:277-282.
16. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.
17. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939-945.
18. De Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet. 1999;354:352-353.
19. Eshoj O, Feldt-Rasmussen B, Larsen ML, Mogensen EF. Comparison of overnight, morning and 24-hour urine collections in the assessment of diabetic microalbuminuria. Diabet Med. 1987;4:531-533.